Preclinical data from myeloma cell lines have suggested synergism when combining a GSI with a novel BH3 mimetic (ABT-737) known to block BCL2/BCLXL to induce apoptosis (17). This evidence concerns the gene BCL2L1 and plasma cell myeloma.